Results 201 to 210 of about 142,808 (332)
Background The activity of CYP2C9, an important drug metabolism enzyme, is subject to the impact of genetic polymorphism. The single nucleotide polymorphism *3 is significantly associated with the increased exposure of CYP2C9 substrates. In addition, metabolic enzyme inhibitors such as fluconazole may also increase the drug exposure of CYP2C9 ...
Shen Cheng +5 more
wiley +1 more source
Abstract Aims Clinical guidelines recommend sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) for individuals with type 2 diabetes mellitus (T2DM) and established or high risk of cardiorenal disease. This study examined real‐world SGLT2i use patterns among older adults with T2DM in British Columbia, Canada.
Hanin Harbi +10 more
wiley +1 more source
NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND HYPERTENSION – DOES AN EXEPTION CHANGE THE RULE?
D. Velickovic +2 more
openalex +1 more source
Abstract Aim Type 2 diabetes (T2D) is associated with increased dementia risk, but comparative data across newer glucose‐lowering therapies remain limited. We examined whether the initiation of GLP‐1 receptor agonists (GLP‐1 RAs) was associated with incident dementia compared with DPP4 inhibitors (DPP4is) and SGLT2 inhibitors (SGLT2is) in older adults ...
Ting Zhou +9 more
wiley +1 more source
Mannitol versus furosemide for prevention of cisplatin-induced nephrotoxicity in a multicenter retrospective cohort study. [PDF]
Harimitsu Y +9 more
europepmc +1 more source
Mode of action of nonsteroidal ecdysone agonists, diacylhydrazine analogs
Chieka Minakuchi
openalex +2 more sources

